THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION PUBLISHES THE RIO-NORTH AMERICA STUDY

Study Shows Rimonabant Maintains Improvements in Multiple Cardiometabolic Risk Factors For Up to Two Years Press Release embargoed until February 14th , 2006 4pm EST/10pm CET. Paris, France, February 14, 2006 – Sanofi-aventis announced that the results of the RIO North America trial were published today in The Journal of the American Medical Association (JAMA). The trial evaluated two-year treatment with rimonabant in overweight or obese patients, many of whom were at increased risk for diabetes and heart disease through the presence of additional risk factors including increased waist circumference (abdominal obesity), elevated blood pressure or abnormal lipid levels. The findings showed that patients treated with rimonabant 20 mg once daily experienced significant reduction of their waist circumference and body weight as well as improvements in multiple cardiometabolic risk factors, including HDL (good) cholesterol, triglycerides and an estimate of insulin sensitivity. Läs hela pressmeddelandet i den bifogade filen.